{"organizations": [], "uuid": "5ff601c036e3b2ae88e5733c4f40a550ac175e45", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/incyte-study/incytes-combo-therapy-for-skin-cancer-fails-in-late-stage-study-idUSL4N1RJ2HG", "country": "US", "domain_rank": 408, "title": "Incyte's combo therapy for skin cancer fails in late-stage study", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-06T14:44:00.000+03:00", "replies_count": 0, "uuid": "5ff601c036e3b2ae88e5733c4f40a550ac175e45"}, "author": "", "url": "https://www.reuters.com/article/incyte-study/incytes-combo-therapy-for-skin-cancer-fails-in-late-stage-study-idUSL4N1RJ2HG", "ord_in_thread": 0, "title": "Incyte's combo therapy for skin cancer fails in late-stage study", "locations": [], "entities": {"persons": [{"name": "arun koyyur", "sentiment": "none"}, {"name": "mrinalini krothapalli", "sentiment": "none"}], "locations": [{"name": "keytruda", "sentiment": "none"}], "organizations": [{"name": "incyte", "sentiment": "negative"}, {"name": "incyte corp", "sentiment": "none"}, {"name": "merck & co", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 6, 2018 / 11:45 AM / Updated 10 minutes ago Incyte's combo therapy for skin cancer fails in late-stage study Reuters Staff 1 Min Read \nApril 6 (Reuters) - Incyte Corp said on Friday an independent committee concluded that its drug in combination with Merck & Coâ€™s Keytruda for a type of skin cancer failed to meet the main goal in a late-stage study. \nThe study did not meet the primary goal of improving progression-free survival in the population compared to Keytruda monotherapy, the two companies said. Reporting by Mrinalini Krothapalli; Editing by Arun Koyyur", "external_links": [], "published": "2018-04-06T14:44:00.000+03:00", "crawled": "2018-04-06T14:59:42.004+03:00", "highlightTitle": ""}